Navigation Links
OncoGenex Announces Publication of Phase I/II Custirsen (OGX-011/TV-1011) Data in Journal of Thoracic Oncology
Date:1/4/2012

BOTHELL, Wash. and VANCOUVER, British Columbia, Jan. 4, 2012 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that data evaluating its investigational compound custirsen (OGX-011/TV-1011) in patients with advanced non-small cell lung cancer (NSCLC) were published in an early online version of the January 2012 issue of the Journal of Thoracic Oncology. These data provide additional clinical evidence for the potential of custirsen, a drug designed to block production of clusterin, a cell survival protein that is commonly overexpressed in several cancer types.

The single-arm trial, conducted at 15 sites in North America, evaluated treatment of custirsen in combination with a gemcitabine/platinum-based regimen in patients with previously untreated, advanced NSCLC. Eighty-one patients received at least one dose of custirsen and were included in the primary analysis. Key study findings are as follows:

  • The median overall survival was 14.1 months and progression-free survival was 4.3 months.
  • The one- and two-year survival rates were 54% and 30%, respectively; twelve percent of patients were still alive at a median follow-up of 41 months (range 38-59 months).
  • 69% of patients had a clinical response defined as objective response or stable disease and 31% of patients had tumor responses defined as complete or partial responses.
  • Custirsen treatment decreased serum clusterin levels in 95% of patients evaluated. In addition, patients who achieved a threshold minimum serum clusterin level of < / = 45 mcg/mL had a median survival of 27.1 months compared to 15.6 months for patients who did not.

The authors concluded that the survival data in this trial compared quite favorably with published data of patients receiving a gemcitabine/platinum-based regimen in a similar dose and schedule, with median survivals of approximately seven to 11 months. Additionally, t
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. OncoGenex Announces Completion of a Special Protocol Assessment (SPA) Amendment with the FDA Increasing Patient Eligibility for the Custirsen Phase III Prostate Cancer SATURN Clinical Trial
2. OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2011 and Provides Update on Development Activities
3. OncoGenex Announces Data Highlighting OGX-427 at American Association of Cancer Research (AACR) 102nd Annual Meeting 2011
4. OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference
5. Isis Pharmaceuticals to Receive $10 Million From OncoGenex License of OGX-011 to Teva
6. OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
7. Echo Therapeutics Announces $3.6 Million Warrant Exercises
8. Shield HealthCare Announces Caregiver Story Contest Winners
9. PDL BioPharma Announces Expiration and Preliminary Results of its Exchange Offer
10. Radient Pharmaceuticals Announces Reverse Stock Split
11. ViroPharma Announces Appointment of Julie H. McHugh to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015 Research and Markets ( http://www.researchandmarkets.com/research/vzhr6h/video ) ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 ... communication has been the topic of fascination since the era ... and the Soviet Russia. Earlier even a small ...
(Date:1/23/2015)... BETHESDA, Md. , Jan. 23, 2015  Northwest Biotherapeutics, Inc. ... developing DCVax® personalized immune therapies for operable and inoperable solid ... will present at the 7 th Annual Phacilitate Immunotherapy ... NW Bio,s presentation at Phacilitate will take place on January ...
(Date:1/23/2015)... Rose, baseball,s all-time hits leader, is the new spokesperson for ... Pharma has announced. "Pete,s a Hall of Famer ... on board with Myoflex," said Ducere Pharma Chief Executive Officer ... is known across all generations. The passion and intensity that ...
Breaking Medicine Technology:Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Pete Rose bets on Myoflex to relieve aches and pains 2
... TOKYO, October 6 Sosei Group Corporation,("Sosei"; TSE ... R&D Ltd., its wholly owned UK subsidiary, has entered,into ... of AD 923, an optimised,sublingual formulation of the opioid ... well as to the device for drug administration to,Pharmasol ...
... The following letter is being released by CEL-SCI ... , Dear Fellow Shareholders: , After FDA had communicated several ... trial with our proposed H1N1 treatment for hospitalized H1N1 patients, ... With this in mind, we have asked one of our ...
Cached Medicine Technology:Sosei Assigns AD 923 Assets to Pharmasol 2CEL-SCI Corporation Releases Letter to Shareholders 2CEL-SCI Corporation Releases Letter to Shareholders 3CEL-SCI Corporation Releases Letter to Shareholders 4CEL-SCI Corporation Releases Letter to Shareholders 5CEL-SCI Corporation Releases Letter to Shareholders 6CEL-SCI Corporation Releases Letter to Shareholders 7
(Date:1/22/2015)... York (PRWEB) January 22, 2015 The federal ... in the U.S. District Court, Southern District of West Virginia ... Inc. in that proceeding’s first bellwether trial. In an Order ... a new trial after finding that C.R. Bard had not ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post ... insurance policy . , Auto insurance quotes help many ... no longer necessary to call an agent or visit an ... on a single website: http://autocarinsurancebest.com/ . , Every business ...
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
(Date:1/22/2015)... January 22, 2015 Four years since the release ... which coincided with the marriage of Avasa & Matthew Love – ... which is scheduled for release through White Swan Records on February ... there is a sacred path available to all of us to ...
(Date:1/22/2015)... a famous dress online store for wedding dresses and other ... of wedding dresses , and launches a site-wide women’s dress ... on your big day; the wedding gown is the most ... find the most suitable wedding dress. Now, we are proud ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... NASHVILLE, Tenn., Nov. 10 Healthcare Realty,Trust Incorporated (NYSE: ... quarter,ended September 30, 2008. Funds from operations ("FFO") per ... same period in 2007. FFO,per diluted common share totaled ... with the prior year,s $1.13. FFO would have been ...
... patients or women who want to delay childbirth , , ... the ability to freeze and transplant ovaries, a development ... therapy. , "We can transplant ovaries without any loss ... normally whether it,s fresh or frozen," said co-researcher Dr. ...
... Omega Protein Corporation,(NYSE: OME ), the nation,s ... products, today reported net income of $3.1 million (17,cents ... to net income of,$7.2 million (42 cents a share) ... (Logo: http://www.newscom.com/cgi-bin/prnh/20030516/OMEGALOGO ), Revenues for the third ...
... Inc. ( www.infotrieve.com ), the global leader in business service solutions ... Content SCM software solution at the biopharma company UCB, headquartered in ... ... EON) November 10, 2008 -- Content SCM is Infotrieve,s revolutionary ...
... Thermage, Inc.,(Nasdaq: THRM ), a leader in ... results for the third quarter ended,September 30, 2008. Reliant ... quarter., Thermage revenue for the third quarter of ... million for the third quarter of 2007. Domestic,revenue decreased ...
... LAKE FOREST, Ill., Nov. 10 Hospira, Inc.,(NYSE: ... medication delivery,company, announced today that Ken Meyers has ... Development. In this,capacity, he will lead the global ... high-performance culture and organizational excellence.,Meyers succeeds Henry Weishaar, ...
Cached Medicine News:Health News:Healthcare Realty Trust Announces Third Quarter Results 2Health News:Healthcare Realty Trust Announces Third Quarter Results 3Health News:Healthcare Realty Trust Announces Third Quarter Results 4Health News:Healthcare Realty Trust Announces Third Quarter Results 5Health News:Healthcare Realty Trust Announces Third Quarter Results 6Health News:Healthcare Realty Trust Announces Third Quarter Results 7Health News:Healthcare Realty Trust Announces Third Quarter Results 8Health News:Healthcare Realty Trust Announces Third Quarter Results 9Health News:Freezing Ovaries Preserves Fertility, Scientists Report 2Health News:Freezing Ovaries Preserves Fertility, Scientists Report 3Health News:Omega Protein Reports 17 Cents Per Share Third Quarter Profit 2Health News:Omega Protein Reports 17 Cents Per Share Third Quarter Profit 3Health News:Omega Protein Reports 17 Cents Per Share Third Quarter Profit 4Health News:Omega Protein Reports 17 Cents Per Share Third Quarter Profit 5Health News: Infotrieve's Revolutionary Content SCM Solution Launched at UCB 2Health News: Infotrieve's Revolutionary Content SCM Solution Launched at UCB 3Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 2Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 3Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 4Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 5Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 6Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 7Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 8Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 9Health News:Hospira Names Ken Meyers to Lead Human Resources 2
... fixation with the Pennig Minifixator, combines the advantage ... procedure. Soft tissue dissection is not necessary, since ... now, external fixation in the hand has required ... of cases (Asche and Burny) because of the ...
The Medium External Fixator has a double-rod frame, medium Combination Clamp medium Multi-Pin Clamp, and Carbon Fiber Rods. Rod Attachment for Medium Multi-Pin Clamp allows second rod to be added....
... a low osmolar ionic dimer. Each ... meglumine, 196 mg of ioxaglate sodium ... disodium as a stabilizer. The solution ... each milliliter and provides 32% (320 ...
... IMAGOPAQUE is a non-ionic monomeric contrast ... in adults and children. After a decade ... 3.5 million examinations, IMAGOPAQUE has proven to ... effort in hundreds of radiology departments.Results from ...
Medicine Products: